Apellis' eye disease drug gets safety label update for rare inflammation side effect
The FDA and Apellis Pharmaceuticals have updated the label for Syfovre — an injection for late-stage wet age-related macular degeneration — to address the potential risk of eye inflammation.
Apellis shares $APLS rose 11% on Friday following the update.
“The new language added to Syfovre’s label is relatively benign,” TD Cowen analyst Phil Nadeau wrote on Friday. Some investors had feared harsher language in the label or a potential boxed safety warning from the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
